.. First ovarian cancer therapy for ST oncology portfolio .. Phase 2 study demonstrated oregovomab in combination with chemotherapy improved progression f...
Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the su...
The agreement covers all 27 countries of the European Union, the UK, Australia, Canada, and New Zealand. Under terms of the agreement, Alvotech will receiv...
Genetic Technologies Limited (GTG), a pioneering global leader in genomics-based tests focused on health, wellness, and the battle against serious diseases...
US-based startup Zenas BioPharma has entered into a license and collaboration agreement with Bristol Myers Squibb Company to develop and commercialise ob...
Australia's Monash University and American firm Moderna have announced the establishment of the Monash-Moderna Quantitative Pharmacology Accelerator (MMQPA...
The Peter Mac Cancer Center is a world leading cancer research, education and treatment center and Australia’s only public health service dedicated t...
Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immu...
INOVIQ and Promega sign a global joint marketing agreement for INOVIQ’s EXO-NET® exosome capture technology and Promega Nucleic Acid purificati...
Microba and Sonic Healthcare signed a commercial agreement to sell Microba's advanced infectious disease testing technology MetaPanel™ in Australia...
Company also issues Deferred Share Units to Board of Directors as Quarterly Director’s Remuneration Entourage Health Corp. (TSX-V: ENTG) (...
PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:PMBHF), a biotechnology company focused on the resear...
New reforestation projects in Brazil, India, Vietnam, Ghana and Rwanda in addition to existing projects including in Australia and Indonesia AstraZeneca h...
First participants have been successfully dosed in a Phase I Clinical Trial of MAP 315, Microba’s lead Therapeutic Program in Inflammatory Bo...
© 2025 Biopharma Boardroom. All Rights Reserved.
